Importantly, BrCa survivors with CIPN continued to demonstrate a higher 1‐year NTFx incidence rate compared to BrCa survivors without CIPN after adjustment for aromatase inhibitor use. The gene discussed is CYP19A1; the disease is invasive breast carcinoma.